Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking TodayThe Motley Fool • 12/29/20
Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestors Business Daily • 12/21/20
Editas surges 50% as ARK founder Cathie Wood sees genomic stocks driving returns for the next 5 years (EDIT)Business Insider • 12/21/20
Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDAGlobeNewsWire • 12/09/20
Editas (EDIT) Up 9.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/20
Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-ThalassemiaGlobeNewsWire • 12/05/20
Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate UpdateGlobeNewsWire • 10/29/20